Gauthier, Alexandra Bleyzac, Nathalie Garnier, Nathalie Kebaili, Kamila Joly, Philippe Goutagny, Marie-Pierre Mollet, Isabelle Goutelle, Sylvain Renard, Cécile Bertrand, Yves
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Graft-versus-host disease (GVHD) is an important challenge and a major cause of morbidity and mortality in children after hematopoietic stem cell transplant (HSCT). Herein we report our institution's experience of goal-oriented Bayesian monitoring for cyclosporine (CsA) used alone as GVHD prophylaxis during the post-transplant period in pediatric p...
Uppuluri, Ramya Swaminathan, Venkateswaran Vellaichamy Ramanan, Kesavan Melarcode Meena, Satishkumar Varla, Harika Ramakrishnan, Balasubramaniam Jayakumar, Indira Raj, Revathi
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Fanconi anemia is the most common inherited bone marrow failure syndrome, and hematopoietic stem cell transplantation (HSCT) is the only curative option. Post-transplant cyclophosphamide (PTCy) is challenging in this group of children, given their increased sensitivity to chemotherapy. We performed a retrospective analysis of the data on children d...
Bhargava, Divya Arora, Mukta DeFor, Todd E Brunstein, Claudio G Thyagarajan, Bharat El Jurdi, Najla Holtan, Shernan G Rashidi, Armin Warlick, Erica Ramesh, Vidhyalakshmi
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
The use of potentially inappropriate medications (PIMs) using Beers criteria and its impact on older allogeneic hematopoietic cell transplantation (HCT) recipients is not known. Here the use of any PIMs and their therapeutic classes in reduced-intensity conditioning allogeneic HCT recipients were compared between older (≥65 years; n = 114) and youn...
Deeg, H Joachim Salit, Rachel B Monahan, Tim Schoch, Gary McFarland, Chris Scott, Bart L Storer, Barry E
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
We investigated risk factors for the development of mixed chimerism in 131 patients who underwent transplantation for myelofibrosis and determined the impact of lymphoid (CD3+) and myeloid (CD33+) chimerism on transplant outcome. Disease risk included DIPSS plus categories low to high. The median patient age was 58 years. Patients were conditioned ...
Yuasa, Mitsuhiro Yamamoto, Hisashi Mitsuki, Takashi Kageyama, Kosei Kaji, Daisuke Taya, Yuki Nishida, Aya Ishiwata, Kazuya Takagi, Shinsuke Yamamoto, Go
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Recent progress in genetic analysis technology has helped researchers understand the pathogenesis of acute myeloid leukemia (AML). Considering this progress, AML karyotype is still one of the most significant prognostic factors that provides risk-adapted treatment approaches. Karyotype changes during treatment have been observed at times, but their...
Algwaiz, Ghada Aljurf, Mahmoud Koh, Mickey Horowitz, Mary M Ljungman, Per Weisdorf, Daniel Saber, Wael Kodera, Yoshihisa Szer, Jeff Jawdat, Dunia
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and the recognition of the variability in practice worldwide, the Worldwide Networ...
Iftikhar, Raheel Chaudhry, Qamar Un Nisa Mahmood, Syed Kamran Ghafoor, Tariq Satti, Humayun Shafique Shahbaz, Nighat Khan, Mehreen Ali Khattak, Tariq Azam Shamshad, Ghassan Umair Rehman, Jahanzeb
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Cyclosporine (CsA) combined with short-course methotrexate is considered standard-of-care graft-versus-host disease (GVHD) prophylaxis for patients with severe aplastic anemia (AA) who undergo transplantation using cyclophosphamide (Cy) plus anti-thymocyte globulin (ATG) conditioning. However, there is no consensus on optimal post-transplant GVHD p...
Politikos, Ioannis Davis, Eric Nhaissi, Melissa Wagner, John E Brunstein, Claudio G Cohen, Sandra Shpall, Elizabeth J Milano, Filippo Scaradavou, Andromachi Barker, Juliet N
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Optimal cord blood (CB) unit selection is critical to maximize the likelihood of successful engraftment and survival after CB transplantation (CBT). However, unit selection can be complex because multiple characteristics must be considered including unit cell dose, donor-recipient human leukocyte antigen (HLA) match, and unit quality. This review p...
Hernández-Boluda, Juan-Carlos Pereira, Arturo Alvarez-Larran, Alberto Martín, Ana-Africa Benzaquen, Ana Aguirre, Lourdes Mora, Elvira González, Pedro Mora, Jorge Dorado, Nieves
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis Transplant Scoring System (MTSS) and identify risk factors for survival in a multicenter series of 197 patients with MF unde...
Lemieux, Christopher Johnston, Laura J Lowsky, Robert Muffly, Lori S Craig, Juliana K Shiraz, Parveen Rezvani, Andrew Frank, Matthew J Weng, Wen-Kai Meyer, Everett
...
Published in
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Plasma cell leukemia (PCL) is a rare and very aggressive plasma cell disorder. The optimal treatment approach, including whether to pursue an autologous (auto) or allogeneic (allo) stem cell transplantation (SCT) is not clear, given the lack of clinical trial-based evidence. This single-center retrospective study describes the outcomes of 16 patien...
